The Initial Public Offerings(IPO) for the week is –
ACHYUT Healthcare Limited-
ACHYUT Healthcare was incorporated in 1996. The company entered into the business of trading pharmaceutical products in 2015 providing customized solutions to its clients. The company is involved in trading in domestic and international markets. It trades around 6-7 products based on customer requirements and exports to countries like UAE, Nigeria, and Kenya. The company intends to expand its global footprint through increased capacities, reduced costs, meeting product specifications, and adhering to global standards.
The company is engaged in trading of Arpimune, Azathioprine IP, Cenzure, Everomimus, Mycophenolate Sodium USP, Sirolimus, Infrared thermometer, Ascorbic Acid coated vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Di basic Calcium Phosphate IP, Di Ethyl Phthalate, Escitalopram IP, Favipiravir and many other products.
The promoters of the company are Mahendra Chtrabhuj Raycha and Akshit Mahendra Raycha. The objective of the IPO is to fund the purchase of machines and equipment and general corporate purposes.
The total revenue of the company was Rs. 66.74 lacs with a loss of Rs. 1.46 lacs (Year ended 31 March 2019), the revenue of Rs. 33.41 lacs with a net profit of Rs. 1.40 lacs (Year ended March 2020) and revenue of Rs. 27.47 lacs with a net profit of Rs. 0.74 lacs (Year ended March 2021).
EVOQ Remedies Limited-
The company was incorporated as ‘Salus Life Science and Research Private Limited’ at Ahmedabad in 2010. The name of the company was changed to ‘EVOQ remedies private limited’ in 2019. EVOQ Remedies is a trading house involved in trading pharmaceutical raw materials, bulk drugs, and excipients. It procures pharmaceutical raw material products from reliable manufacturers and importers who follow procedures according to the strict national and international safety standards.
EVOQ is involved in the trading of excipients, pellets, nutraceuticals, solvents, sweeteners, vitamins, amino acids, bulk drugs, dairy products, and active pharmaceutical ingredients. The promoter of the company is Mr. Bhumishth Narendrabhai Patel and Mrs. Payal Bhumishth Patel. The objects of the issue are to meet incremental working capital requirements and general corporate purposes. Listing would enhance the visibility and brand image of the company.
The total revenue of the company was Rs. 3.25 crore with a net profit of Rs. 1.11 lacs (Year ended 31 March 2019), the revenue of Rs. 9.07 crore with a net profit of Rs. 0.03 lacs (Year ended March 2020) and revenue of Rs. 10.02 crore with a net profit of Rs. 71.38 lacs (Year ended March 2021).
P.E. Analytics is engaged in providing real estate business intelligence and analytics platform to developers, the construction industry, banks, investors, housing finance companies, equity research firms, real estate PE funds, REITS, HNIs, lenders, and investors in real estate. The company has transformed itself into a business intelligence platform for real estate in India due to its in-depth research, authentic database, and years of experience. The company provides real estate data analytics and market research reports pricing on an annual subscription basis and on an ad hoc basis according to the requirements of the users.
The business lines of the company are characterized by high entry barriers, market-leading position, and PAN India footprint. The database of the company covers pan India footprint across 44 cities with the real estate data covering more than 180 data points. It has coverage of over 42,000 developers, 1,36,000 projects and 97, 00,000 units. P.E analytics company adds approximately 300 projects every month.
The promoter of the company is Mr. Samir Jasuja. The company will utilize the proceeds of the IPO for the objectives as mentioned; expenditure for technology up-gradation, retail initiative (B2C expansion plan), and general corporate purpose.
The total revenue of the company was Rs. 14.88 crores with a net profit of Rs. 3.47 crore (Year ended 31 March 2019), the revenue of Rs. 15.62 crore with a net profit of Rs. 1.17 crore (Year ended March 2020) and revenue of Rs. 18.01 crore with a net profit of Rs. 6.92 crore (Year ended March 2021).